Vlasios S. Sotirchos MD, Presenter: Nothing to Disclose

Efsevia Vakiani MD, Abstract Co-Author: Nothing to Disclose

Sho Fujisawa PhD, Abstract Co-Author: Nothing to Disclose

Yevgeniy Romin, Abstract Co-Author: Nothing to Disclose

Mesruh Turkekul, Abstract Co-Author: Nothing to Disclose

Karen Teresa Brown MD, Abstract Co-Author: Nothing to Disclose

Elena Nadia Petre MD, Abstract Co-Author: Nothing to Disclose

Stephen Barnett Solomon MD, Abstract Co-Author: Research Grant, General Electric Company Research Grant, AngioDynamics, Inc Consultant, Johnson & Johnson Consultant, Covidien AG Director, Devicor Medical Products, Inc Director, Aspire Bariatrics, Inc

Alessandra Garcia, Abstract Co-Author: Nothing to Disclose

Katia Manova-Todorova, Abstract Co-Author: Nothing to Disclose

Constantinos Thasos Sofocleous MD, PhD, Abstract Co-Author: Consultant, Sirtex Medical Ltd

To evaluate live cell fluorescent assessment as an immediate biomarker of complete ablation of colorectal cancer liver metastases (CLMs).

This NIH-supported IRB-approved prospective study analyzed live tissue collected from the center and the margin of the percutaneous ablation zone of CLMs. 18-20 gauge core biopsy specimens collected from the ablation zone underwent fluorescent staining that generated composite images of nuclear Hoechst and MitoTracker Red stains within 30 minutes from radio frequency ablation. Subsequently, the exact same tissue samples were fixated and stained with standard H&E morphologic stains. A blinded pathologist classified the composite fluorescent images into viable tumor vs. coagulation necrosis and normal liver cells. These were correlated with the blinded interpretation of the standard H&E morphologic stain.

Initial results from 25 collected specimens in 14 patients with 15 ablated CLMs demonstrated a concordance rate of 88% (22/25) when assessing for the presence of tumor cells. Fluorescent stain sensitivity was 80% (4/5) for specimens positive on standard H&E for tumor cells; Specificity was 90% (18/20).

Given the documented prognostic value of tissue characteristics on local tumor progression-free and overall survival in patients with CLMs, ablation zone evaluation with fluorescent stains may provide an immediate assessment of the ablation success and guide immediate or future additional therapies.

Fluorescence imaging of liver tissue from the ablation zone may provide intraprocedural assessment of technical failure and guide decisions for additional therapy.

Sotirchos, V, Vakiani, E, Fujisawa, S, Romin, Y, Turkekul, M, Brown, K, Petre, E, Solomon, S, Garcia, A, Manova-Todorova, K, Sofocleous, C, Evaluation of Fluorescent Stains as Real-time Assessment of Incomplete Ablation of Colon Cancer Liver Metastases.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14045793.html